Methylation of CpG sites in RNF180 DNA promoter prediction poor survival of gastric cancer
Metrics: PDF 2045 views | HTML 1938 views | ?
Jingyu Deng1, Han Liang1, Guoguang Ying2, Rupeng Zhang1, Baogui Wang1, Jun Yu3, Daiming Fan4, and Xishan Hao1
1 Department of Gastroenterology, Tianjin Medical University Cancer Hospital, City Key Laboratory of Tianjin Cancer Center and National Clinical Research Center for Cancer, Tianjin, China
2 Central laboratory, Tianjin Medical University Cancer Hospital, City Key Laboratory of Tianjin Cancer Center and National Clinical Research Center for Cancer, Tianjin, China
3 Institute of Digestive Disease, Li Ka Shing Institute of Health Science, Chinese University of HongKong, Shatin, HongKong
4 State Key Laboratory of Cancer Biology and Institute of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi’an, China
Xishan Hao, email:
Han Liang, email:
Keywords: Ring finger protein 180, Lymph node, Methylation, Prognosis, Gastric cancer
Received: March 24, 2014 Accepted: April 07, 2014 Published: April 08, 2014
RNF 180, a novel tumor suppressor, has been implicated in the carcinogenesis and progress of gastric cancer. At present study, we found that lower expression of RNA180 was specific in gastric cancer tissues, and the inconsistently methylated levels of RNF180 promoter were identified in the gastric cancer tissues. Importantly, we demonstrated that the methylated CpG site count and four hypermethylated CpG sites (-116, -80, +97, and +102) were significantly associated with the survival of 400 gastric cancer patients, respectively. With multivariate survival analyses, we demonstrated that both the methylation of combined CpG (-116, -80, +97, and +102) sites and N stage were the independent indictor of prognosis of gastric cancer patients. Eventually, the methylation of combined CpG (-116, -80, +97, and +102) sites was identified to have smaller AIC value than N stage by mean of AIC calculation with the Cox proportional hazards model. These findings indicated that the quantitative detection of RNF180 promoter methylation had the intensive feasibility for evaluation the prognosis of gastric cancer patients in clinic.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.